Prostamax
A Khavinson short-peptide 'prostate bioregulator' (Lys-Glu-Asp-Pro) positioned to support prostate tissue in benign prostatic hyperplasia and chronic prostatitis.
Prostamax is a short synthetic peptide developed in Russia by Vladimir Khavinson and collaborators at the St. Petersburg Institute of Bioregulation and Gerontology, described in Khavinson-family publications as the tetrapeptide Lys-Glu-Asp-Pro (KEDP). It is the defined-sequence counterpart to Prostatilen (marketed as Vitaprost), a bovine-prostate polypeptide extract registered as a Russian pharmaceutical for BPH and chronic prostatitis. It is positioned as a prostate bioregulator intended to support prostatic epithelium and stromal function, but outside Russia it has no FDA, EMA, or major Western regulatory approval and does not appear in AUA, EAU, or NICE guidelines.
Class
Synthetic prostate-targeted tetrapeptide bioregulator (Khavinson short-peptide family)
Routes
Oral capsule, Sublingual, Subcutaneous injection, Rectal suppository (extract/parent form)
Category
Longevity & Bioregulators
Researched benefits
What it's studied for
Prostate health maintenance
Positioned to support prostatic epithelium and stromal homeostasis in age-related prostate decline. Evidence is limited to Khavinson-group in vitro work and uncontrolled observational series; the parent extract has modestly more clinical support.
Benign prostatic hyperplasia (BPH) support
Used in Russian clinical practice for BPH, with Khavinson-group and parent-extract trials reporting improvements in urological (IPSS) symptom scores and prostate volume parameters. Independent Western replication is limited.
Chronic prostatitis support
The parent extract (Prostatilen/Vitaprost) has Russian RCT-style trials reporting IPSS improvement and reduced prostate-specific inflammation markers in chronic prostatitis and chronic pelvic pain syndrome; whether synthetic KEDP reproduces these effects has not been systematically tested.
Prostate tissue repair and post-surgical recovery
Proposed as an adjunct for post-surgical prostate recovery within the Khavinson framework, based on the model of preferential activation of prostatic homeostatic transcription programmes. No modern biodistribution or prostate-specific transcriptomic validation exists.
Anti-aging effects on prostate tissue
Marketed in longevity and male-health contexts as a bioregulator that downregulates hyperproliferative and inflammatory patterns while supporting glandular function. This is a framework-level hypothesis rather than measured pharmacology.
Mechanism
How it works
Prostamax's proposed mechanism is the standard Khavinson short-peptide model applied to prostate tissue: passive membrane permeation, nuclear import, and sequence-selective chromatin modulation producing prostate-favourable transcriptional shifts. At roughly 473 daltons (H-Lys-Glu-Asp-Pro-OH), the peptide is small and sufficiently polar that it is proposed to cross phospholipid bilayers passively, with Khavinson tritiated-peptide biodistribution work describing uptake across multiple tissues (Khavinson et al., 2014).
The framework-level claim is zone- or cell-type-selective prostate uptake, followed by preferential activation of prostatic homeostatic transcription programmes and downregulation of inflammatory and hyperproliferative patterns. Russian in vitro work describes modulation of prostatic epithelial cell proliferation, reduced apoptosis markers under stress, and changes in androgen-receptor signalling markers in cultured prostate cells (Khavinson et al., 2011). However, no direct experimental validation of tissue-selective targeting exists, and modern methods (single-cell transcriptomics on prostate organoids, ChIP-seq, CRISPR target validation) have not been applied.
No GPCR, nuclear receptor, or defined enzyme target has been identified for Prostamax. It does not bind the androgen receptor, alpha-adrenoceptors, or PDE5, does not inhibit 5-alpha reductase, and does not directly affect COX, LOX, or NF-kB inflammatory pathways at characterised concentrations. This absence of a defined pharmacological target is characteristic of the Khavinson bioregulator class.
A parsimonious alternative framing treats Prostamax as an amino-acid source delivering lysine, glutamate, aspartate, and proline, with any biological effects potentially reflecting substrate delivery for prostatic protein synthesis, proline-mediated collagen synthesis in stroma, glutamate/aspartate TCA-cycle anaplerosis, or non-specific nutritional support. It also remains an open question whether the active component of the parent extract is KEDP, a different peptide, or a mixture of factors.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
For synthetic lyophilised KEDP peptide (research suppliers only): warm the vial to room temperature, flick to dislodge the lyophilisate, and clean the stopper. Add 2 mL bacteriostatic water to a 5 mg vial for a 2.5 mg/mL concentration (inject slowly down the glass and let dissolve 5-10 minutes). At 2.5 mg/mL: 2 mg = 0.8 mL (80 units), 2.5 mg = 1.0 mL (100 units), 5 mg = 2.0 mL. Store at 2-8 C (do not freeze); ~28-30 day stability; discard if cloudy. Prostatilen/Vitaprost suppositories are ready-to-use and require no reconstitution.
Beginner
- Dose
- 1 capsule (20 mg nominal) once daily
- Frequency
- Once daily
- Timing
- Sublingual (~60 seconds) or oral on an empty stomach, 30-45 min before breakfast
- Duration
- 10 consecutive days, then 60-day washout before repeat
- Route
- Oral / sublingual
Establish baseline first: PSA (age/risk appropriate), IPSS score, urinalysis, and urologist evaluation if moderate-severe symptoms. Track urinary frequency, urgency, nocturia, flow and post-void satisfaction daily. Continue existing prostate therapy. Stop for acute urinary retention, haematuria, fever with urinary symptoms, severe worsening, or rash. Expect mild subjective effects at best.
Intermediate
- Dose
- 20 mg oral daily OR 2-5 mg SC daily OR 1 suppository daily
- Frequency
- Once daily
- Timing
- Oral/sublingual on empty stomach, or SC with site rotation
- Duration
- 10 consecutive days per cycle, typically twice yearly
- Route
- Oral / sublingual / subcutaneous / rectal (extract form)
For experienced bioregulator users. Rotate with Testagen in alternating cycles for broader male-reproductive support. Monitor with annual PSA (age-appropriate), annual IPSS, and post-void residual if symptomatic. Continue evidence-graded BPH therapy; Prostamax is an experimental layer. Annual cycling runs roughly 150-400 USD versus far cheaper generic pharmacotherapy.
Advanced
- Dose
- 20 mg oral/sublingual daily OR 5 mg SC daily
- Frequency
- Once daily during 10-day blocks within an annual rotation
- Timing
- Oral/sublingual or SC
- Duration
- Month 1 days 1-10 Prostamax; months 2-3 washout; month 4 Testagen; months 5-6 washout; month 7 Epitalon; months 8-9 washout; month 10 Prostamax repeat; months 11-12 washout
- Route
- Oral / sublingual / subcutaneous
For experienced Khavinson users with established prostate monitoring. Stack on an evidence-graded base (alpha-blocker, 5-ARI, PDE5 inhibitor per urology; saw palmetto, Pygeum, beta-sitosterol as supplement layer). Baseline and annual PSA, annual DRE (age-appropriate), quarterly IPSS. Coordinate with urology with full disclosure; stop and reassess for rising PSA, new symptoms, haematuria, or retention.
Rectal suppository (extract/parent form)
- Dose
- 50 mg suppository
- Frequency
- 1-2 times daily
- Timing
- Per manufacturer label
- Duration
- 10-14 day courses, repeat every 3-6 months as needed
- Route
- Rectal
Vitaprost/Prostatilen is the Russian-pharmaceutical form of the parent polypeptide extract, not directly equivalent to synthetic KEDP oral dosing but occupying the same therapeutic niche. Do not use within 48 hours of a PSA blood draw, as rectal manipulation could theoretically elevate PSA.
- The 20 mg oral capsule contains an undisclosed actual KEDP content, historically cited at approximately 2-4 mg.
- 10-on / 60-off cycling is Khavinson convention; the parent extract typically uses 10-14 day suppository courses. Do not run continuous cycles.
- Maximum dose: do not exceed 20 mg oral or 5 mg SC daily, and do not exceed the manufacturer label for the extract suppository form.
- Oral and subcutaneous routes do not affect PSA timing, but avoid the rectal suppository within 48 hours of PSA testing.
- No paediatric or adolescent use; Russian studies enrol men aged 50+ with BPH or chronic prostatitis.
- No formal renal/hepatic dose adjustment is defined; avoid in severe impairment.
- Use only third-party HPLC-verified product; for suppository form, pharmaceutical-grade manufacturing is required.
- Prostamax is a speculative experimental adjunct, not a substitute for evidence-graded BPH pharmacotherapy (alpha-blockers, 5-alpha reductase inhibitors, PDE5 inhibitors).
Evidence
Research & clinical studies (5)
Khavinson-group in vitro studies of prostatic peptide effects on cultured prostate cells
Reported modulation of prostatic epithelial cell proliferation, reduced apoptosis markers under stress, and changes in androgen-receptor signalling markers in cultured prostate cells.
Khavinson tritiated short-peptide biodistribution studies
Tritiated-peptide work describes uptake of Khavinson short peptides across multiple tissues, cited to support the passive-permeation and tissue-distribution model.
Prostatilen/Vitaprost polypeptide extract trials in BPH and chronic prostatitis (Kuznetsov et al.)
Russian RCT-style trials of the parent extract reported improvements in IPSS scores, prostate-specific inflammation markers, and ejaculate quality in BPH, chronic prostatitis, and associated male infertility.
Prostatilen/Vitaprost extract trials in BPH symptom scores (Avdoshin et al.)
Reported benefit of the parent polypeptide extract in chronic pelvic pain syndrome and BPH symptom scores.
Anisimov and colleagues, Khavinson short-peptide bioregulator research
Part of the small-rodent and observational evidence base underlying the synthetic Prostamax tetrapeptide within the Khavinson bioregulator program.
Combinations
Stacking & blends
Male-reproductive Khavinson rotation
Broad male-reproductive and longevity bioregulation across an annual cycle
Prostamax (prostate) is alternated with Testagen (testis) and Epitalon (pineal/telomere) in separate 10-day blocks with washouts, applying tissue-specific Khavinson peptides in sequence for comprehensive male-health support.
Prostamax + Testagen alternating cycles
Prostate plus testicular bioregulatory support
Listed as synergistic and paired in alternating cycles for broader male-reproductive support; both are Khavinson tissue-targeted peptides addressing complementary organs.
Evidence-graded BPH base plus bioregulator layer
Add an experimental bioregulator on top of proven BPH therapy
Prostamax is layered on a foundation of alpha-blockers, 5-alpha reductase inhibitors, and/or PDE5 inhibitors (plus saw palmetto, Pygeum, beta-sitosterol) rather than substituting for them, since no pharmacokinetic or pharmacodynamic interactions with standard BPH medications are documented.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Active prostate cancer or recent history
- Elevated PSA under investigation (complete workup first)
- Unexplained haematuria (evaluate before use)
- Acute urinary retention (medical emergency)
- Active bacterial prostatitis or UTI (antibiotic therapy required)
- Known hypersensitivity to Prostamax or any Khavinson bioregulator
- Bovine/porcine protein allergy (for extract/suppository form)
- Paediatric and adolescent use
- Recent prostate surgery (within 6 weeks) or active radiation therapy to the prostate (supervised use only)
- Severe renal or hepatic impairment
The short-term safety signal from Russian literature is mild, with no serious urological adverse events reported at convention dosing, but long-term pharmacovigilance is absent and independent verification is limited. Symptoms such as blood in urine, dysuria with fever, acute urinary retention, rising PSA, new haematospermia, weight loss with urinary symptoms, or bone pain require urological evaluation, not bioregulator self-treatment. Maintain standard PSA surveillance appropriate for age and risk, and use only third-party HPLC-verified product.
FAQ
Prostamax — common questions
What is Prostamax and what is it claimed to do?
Prostamax is a synthetic tetrapeptide (Lys-Glu-Asp-Pro, KEDP) from Vladimir Khavinson's St. Petersburg Institute, positioned as a prostate bioregulator for benign prostatic hyperplasia, chronic prostatitis, and age-related prostate decline. It is the defined-sequence counterpart to Prostatilen (Vitaprost), a registered Russian bovine-prostate polypeptide extract. Claims include supporting prostatic epithelium and stromal function and modulating inflammatory and hyperproliferative patterns. It is not FDA/EMA-approved and should be treated as experimental.
Is Prostamax a single peptide or an extract?
Synthetic Prostamax is a single defined tetrapeptide, Lys-Glu-Asp-Pro (KEDP), with a molecular weight around 472.48 g/mol. Its parent compound, Prostatilen/Vitaprost, is a polypeptide extract prepared from bovine prostate tissue and is a registered Russian pharmaceutical. It is an open question whether synthetic KEDP reproduces the effects of the parent extract.
Does Prostamax actually help with BPH or prostatitis?
The parent extract (Prostatilen/Vitaprost) has modestly more evidence than the synthetic tetrapeptide, including Russian RCT-style trials reporting IPSS improvement in chronic prostatitis and BPH. The synthetic Prostamax evidence base is substantially smaller, comprising Khavinson-group in vitro work and uncontrolled observational series. For evidence-graded BPH management, first-line therapy is alpha-blockers, 5-alpha reductase inhibitors for larger prostates, and PDE5 inhibitors for LUTS/ED overlap; Prostamax is a speculative adjunct, not a substitute.
What is the correct Prostamax dose?
Khavinson convention is a 20 mg oral or sublingual capsule once daily for 10 consecutive days with 60-90 day washouts (the 20 mg capsule contains an undisclosed actual KEDP content, historically 2-4 mg). For the synthetic peptide, subcutaneous dosing is 2-5 mg daily for 10 days. The rectal suppository extract form (Prostatilen/Vitaprost) is typically 50 mg rectally 1-2 times daily for 10-14 days per manufacturer label. Do not use the suppository form within 48 hours of PSA testing.
How does Prostamax compare to tamsulosin, finasteride, and prescription BPH drugs?
Prescription BPH drugs sit at a fundamentally higher evidence tier. Tamsulosin produces measurable urinary flow improvement within days through mapped alpha-1A receptor blockade; finasteride reduces prostate size by roughly 25% over 6-12 months; tadalafil improves LUTS and ED via the NO/cGMP pathway. All are RCT-validated, FDA-approved, and in every major urological guideline. Prostamax is a framework-level hypothesis about chromatin, not measured pharmacology, and should be considered only as an experimental adjunct.
Is Prostamax safe?
The short-term safety signal from Russian literature is mild, with occasional nausea, headache, rare rash, and mild local irritation from the suppository form, and no serious urological adverse events at convention dosing. However, long-term pharmacovigilance is absent. It is contraindicated in active prostate cancer, elevated PSA under investigation, unexplained haematuria, acute urinary retention, active bacterial prostatitis, and (for the extract form) bovine/porcine protein allergy. Use only HPLC-verified product and maintain PSA surveillance.
Can I use Prostamax with my existing BPH medications?
Yes, from an interaction standpoint. No documented pharmacokinetic or pharmacodynamic interactions exist between Prostamax and alpha-blockers, 5-alpha reductase inhibitors, PDE5 inhibitors, or antimuscarinics. Continue prescription BPH therapy through Prostamax cycles rather than substituting, and notify your urologist of any bioregulator use.
Can Prostamax prevent or treat prostate cancer?
No. Prostamax has no evidence for prostate cancer prevention or treatment and is explicitly contraindicated in active prostate cancer. The theoretical chromatin-modulating mechanism raises concern, not established benefit, in proliferative disease of the target organ. Anyone diagnosed with prostate cancer should consult oncology and urology immediately.
